• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

M&A Deal Activity Slows In First Three Quarters Of 2019

Share:

October 7, 2019

  • Global dealmaking grinds to the slowest pace in more than two years as fears of an economic slowdown deflate corporate confidence and a $200B tobacco industry merger was scuttled due to shareholder criticism.
  • So far this year, total M&A activity has fallen 11% to $2.8T, with ~$740B of deals in Q3, according to data provider Refinitiv.
  • A wave of transactions greater than $10B in size have helped to offset a decline in dealmaking among smaller companies and a slight drop-off in private equity buyouts.
  • The three months to the end of September was the quietest quarter for announced takeovers since mid-2017.
  • European dealmaking fell 32% to $556B vs. the same period a year ago. Activity in Asia was also off sharply.
  • Data from Refinitiv shows M&A fees earned by Citi (NYSE:C), Morgan Stanley (NYSE:MS), UBS (NYSE:UBS), and Credit Suisse (NYSE:CS) are all off at least 20% YTD.

Date: October 07, 2019

Source: Seeking Alpha

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • LGM Pharma Acquires Pharmaceutical Development and Manufacturing Unit of Nexgen PharmaLGM Pharma Acquires Pharmaceutical Development and Manufacturing Unit of Nexgen Pharma
  • HCPs: Breaking Through the Noise with Digital EngagementHCPs: Breaking Through the Noise with Digital Engagement
  • Ani Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd.Ani Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd.
  • Timing of State and Territorial COVID-19 Stay-at-Home Orders and Changes in Population Movement — United States, March 1–May 31, 2020Timing of State and Territorial COVID-19 Stay-at-Home Orders and Changes in Population Movement — United States, March 1–May 31, 2020
  • Castle Creek Pharmaceutical Holdings to Acquire FibrocellCastle Creek Pharmaceutical Holdings to Acquire Fibrocell
  • Bioniz Therapeutics Enters Into An Option Agreement for Acquisition By Almirall of Its Lead Clinical Candidate BNZ-1 in Development for Immuno-dermatologic and Onco-Dermatologic DiseasesBioniz Therapeutics Enters Into An Option Agreement for Acquisition By Almirall of Its Lead Clinical Candidate BNZ-1 in Development for Immuno-dermatologic and Onco-Dermatologic Diseases
  • Emblemhealth Announces Partnership with Medly Pharmacy for Prescription Home Delivery Services as Covid-19 Cases IncreaseEmblemhealth Announces Partnership with Medly Pharmacy for Prescription Home Delivery Services as Covid-19 Cases Increase
  • NeoTX Closes $45 Million Series C FinancingNeoTX Closes $45 Million Series C Financing

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications